



## Living Cell Technologies Limited Company Announcement

### Living Cell Technologies Founder wins Prestigious Award

- Founder Professor Robert Elliott wins “World Class New Zealand Award”
- Honoured for his important international contribution to life sciences
- Recognises LCT’s position as a leading international biotechnology company

**Living Cell Technologies**, a global company pioneering the development of a cell implant therapy to treat diabetes, today announced that Medical Director and founder Professor Robert Elliott has been awarded the prestigious “World Class New Zealand Award.” The Awards are described as one of the country’s most important accolades for outstanding individuals who have made major contributions to New Zealand’s success on the world stage.

“It’s a great honour to receive this recognition for my life’s work to find an effective treatment for diabetes,” says Dr. Bob Elliott. “We see the great need to improve the health and lifestyles of people with diabetes and I am very appreciative that the award selection committee has acknowledged the contribution our revolutionary DIABECCELL<sup>®</sup> treatment will make to the world.”

DIABECCELL, now in final stages of Phase II clinical trials, is designed to help normalise the lives of people with unstable Type 1 diabetes. Tiny DIABECCELL microspheres containing live islet cells are implanted into a patient’s abdomen using a simple laparoscopic procedure. Once implanted, DIABECCELL works by self-regulating and efficiently secreting insulin and glucagon in response to the patient’s changing glucose levels.

This is the eighth year that leaders in fields, including life sciences, business and finance have received the World Class New Zealand Awards. They are sponsored by the federal department, New Zealand Trade and Enterprise, and KEA, an organisation dedicated helping connect New Zealand with the rest of the world through building a network of global citizens who take an active interest in the future of the country.

LCT CEO and Managing Director Dr Ross Macdonald said: “Bob is a very deserving person for this award. He has dedicated his life to improving people’s health and finding effective treatments for a range of disease. While he gets most attention for work in Diabetes, Bob is also leading the development of treatments for other illnesses, including Parkinson’s disease.”

“Few also know that he helped with the development of a type of milk now widely available in supermarkets, which is high in the A2 protein and offers a range of health benefits. We are very proud of his contributions to New Zealand and the world.”

The awards will be presented Wednesday, 6 April at a black-tie gala in Auckland. Other winners can be found at <http://www.keanewzealand.com/sites/default/files/2011-wcnz-awards.pdf>.

For further information: [www.lctglobal.com](http://www.lctglobal.com)

|  |   |
|--|---|
| <b>At the company:</b><br>Ms Susanne Clay<br>Chief Business Officer, Living Cell Technologies<br>Tel: +64 9 270 7954<br>Mobile: +64 21 418 833<br><a href="mailto:sclay@lctglobal.com">sclay@lctglobal.com</a> | <b>Media and investor enquiries:</b><br>NZ and Australia:<br>Buchan Consulting<br>Rebecca Wilson<br>Tel: +61 3 9866 4722<br>Mobile: +61 417 382 391<br><a href="mailto:rwilson@bcg.com.au">rwilson@bcg.com.au</a> |
|--|---|

**About Living Cell Technologies - [www.lctglobal.com](http://www.lctglobal.com)**

Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases. The Company owns a biocertified pig herd that it uses as a source of cells for treating diabetes and neurological disorders. For patients with Type 1 diabetes, the Company transplants microencapsulated islet cells so that near-normal blood glucose levels may be achieved without the need for administration of insulin or at significantly reduced levels. The Company entered clinical trials for its diabetes product in 2007. For the treatment of Parkinson's disease and other neurological disorders, the company transplants microencapsulated choroid plexus cells that deliver beneficial proteins and neurotrophic factors to the brain. LCT's technology enables healthy living cells to be injected into patients to replace or repair damaged tissue without requiring the use of immunosuppressive drugs to prevent rejection. LCT also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.

**LCT Disclaimer**

*This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.*